{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:05:07Z","timestamp":1790701507945,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T00:00:00Z","timestamp":1486771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T00:00:00Z","timestamp":1486771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["NIH T32 HL007062-34"],"award-info":[{"award-number":["NIH T32 HL007062-34"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00520-017-3614-y","type":"journal-article","created":{"date-parts":[[2017,2,11]],"date-time":"2017-02-11T17:33:50Z","timestamp":1486834430000},"page":"1687-1698","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["A systematic review of the impact of pain on overall survival in patients with cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Dylan","family":"Zylla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,11]]},"reference":[{"issue":"8","key":"3614_CR1","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","volume":"20","author":"H Breivik","year":"2009","unstructured":"Breivik H et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20(8):1420\u20131433","journal-title":"Ann Oncol"},{"issue":"18","key":"3614_CR2","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1001\/jama.290.18.2476","volume":"290","author":"E Bruera","year":"2003","unstructured":"Bruera E, Kim HN (2003) Cancer pain. JAMA 290(18):2476\u20132479","journal-title":"JAMA"},{"issue":"9","key":"3614_CR3","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","volume":"18","author":"MH van den Beuken-van Everdingen","year":"2007","unstructured":"van den Beuken-van Everdingen MH et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40\u00a0years. Ann Oncol 18(9):1437\u20131449","journal-title":"Ann Oncol"},{"issue":"10","key":"3614_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00520-006-0079-9","volume":"14","author":"CA Hauser","year":"2006","unstructured":"Hauser CA, Stockler MR, Tattersall MH (2006) Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review. Support Care Cancer 14(10):999\u20131011","journal-title":"Support Care Cancer"},{"key":"3614_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri A (2009) Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7:102","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3614_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.critrevonc.2012.02.011","volume":"84","author":"M Trajkovic-Vidakovic","year":"2012","unstructured":"Trajkovic-Vidakovic M et al (2012) Symptoms tell it all: a systematic review of the value of symptom assessment to predict survival in advanced cancer patients. Crit Rev Oncol Hematol 84(1):130\u2013148","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"3614_CR7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S1470-2045(09)70200-1","volume":"10","author":"C Quinten","year":"2009","unstructured":"Quinten C et al (2009) Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 10(9):865\u2013871","journal-title":"Lancet Oncol"},{"issue":"15","key":"3614_CR8","first-page":"4491","volume":"62","author":"K Gupta","year":"2002","unstructured":"Gupta K et al (2002) Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res 62(15):4491\u20134498","journal-title":"Cancer Res"},{"issue":"11","key":"3614_CR9","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/sj.bjc.6604057","volume":"97","author":"M Farooqui","year":"2007","unstructured":"Farooqui M et al (2007) COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia. Br J Cancer 97(11):1523\u20131531","journal-title":"Br J Cancer"},{"issue":"3","key":"3614_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1213\/ANE.0b013e31820568af","volume":"112","author":"B Mathew","year":"2011","unstructured":"Mathew B et al (2011) The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg 112(3):558\u2013567","journal-title":"Anesth Analg"},{"issue":"Suppl 1","key":"3614_CR11","doi-asserted-by":"publisher","first-page":"i103","DOI":"10.1093\/bja\/aeu165","volume":"113","author":"PA Singleton","year":"2014","unstructured":"Singleton PA et al (2014) Increased mu-opioid receptor expression in metastatic lung cancer. Br J Anaesth 113(Suppl 1):i103\u2013i108","journal-title":"Br J Anaesth"},{"issue":"2","key":"3614_CR12","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/dote.12165","volume":"28","author":"YF Zhang","year":"2015","unstructured":"Zhang YF et al (2015) Association of mu-opioid receptor expression with lymph node metastasis in esophageal squamous cell carcinoma. Dis Esophagus 28(2):196\u2013203","journal-title":"Dis Esophagus"},{"issue":"23","key":"3614_CR13","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1002\/cncr.28345","volume":"119","author":"D Zylla","year":"2013","unstructured":"Zylla D et al (2013) Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer. Cancer 119(23):4103\u20134110","journal-title":"Cancer"},{"key":"3614_CR14","doi-asserted-by":"crossref","unstructured":"Zylla, D., et al. 2014., Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer. Br J Anaesth,","DOI":"10.1093\/bja\/aeu351"},{"issue":"12","key":"3614_CR15","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1200\/JCO.1992.10.12.1833","volume":"10","author":"A Coates","year":"1992","unstructured":"Coates A et al (1992) Prognostic value of quality-of-life scores during chemotherapy for advanced breast cancer. Australian New Zealand breast cancer trials group. J Clin Oncol 10(12):1833\u20131838","journal-title":"J Clin Oncol"},{"issue":"7","key":"3614_CR16","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ejca.2004.01.014","volume":"40","author":"F Efficace","year":"2004","unstructured":"Efficace F et al (2004) Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer. Eur J Cancer 40(7):1021\u20131030","journal-title":"Eur J Cancer"},{"issue":"12","key":"3614_CR17","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0959-8049(00)00144-1","volume":"36","author":"JA Kramer","year":"2000","unstructured":"Kramer JA et al (2000) Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer 36(12):1498\u20131506","journal-title":"Eur J Cancer"},{"issue":"9","key":"3614_CR18","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/sj.bjc.6605649","volume":"102","author":"CK Lee","year":"2010","unstructured":"Lee CK et al (2010) Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer. Br J Cancer 102(9):1341\u20131347","journal-title":"Br J Cancer"},{"issue":"10","key":"3614_CR19","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S0959-8049(02)00775-X","volume":"39","author":"ML Luoma","year":"2003","unstructured":"Luoma ML et al (2003) Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer. Eur J Cancer 39(10):1370\u20131376","journal-title":"Eur J Cancer"},{"issue":"6","key":"3614_CR20","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1524-4741.2011.01151.x","volume":"17","author":"ED Staren","year":"2011","unstructured":"Staren ED, Gupta D, Braun DP (2011) The prognostic role of quality of life assessment in breast cancer. Breast Journal 17(6):571\u2013578","journal-title":"Breast Journal"},{"issue":"2","key":"3614_CR21","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12032-011-9844-9","volume":"29","author":"H Svensson","year":"2012","unstructured":"Svensson H et al (2012) Health-related quality of life as prognostic factor for response, progression-free survival, and survival in women with metastatic breast cancer. Med Oncol 29(2):432\u2013438","journal-title":"Med Oncol"},{"key":"3614_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1477-7525-12-69","volume":"12","author":"M Diouf","year":"2014","unstructured":"Diouf M et al (2014) Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study. Health Qual Life Outcomes 12:69","journal-title":"Health Qual Life Outcomes"},{"issue":"1","key":"3614_CR23","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ejca.2005.07.025","volume":"42","author":"F Efficace","year":"2006","unstructured":"Efficace F et al (2006) Does a patient's self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur J Cancer 42(1):42\u201349","journal-title":"Eur J Cancer"},{"issue":"12","key":"3614_CR24","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2007.12.3117","volume":"26","author":"F Efficace","year":"2008","unstructured":"Efficace F et al (2008) Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for research and treatment of cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(12):2020\u20132026","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"issue":"10","key":"3614_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/S0959-8049(02)00098-9","volume":"38","author":"NR Maisey","year":"2002","unstructured":"Maisey NR et al (2002) Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 38(10):1351\u20131357","journal-title":"Eur J Cancer"},{"issue":"1","key":"3614_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1245\/s10434-009-0737-5","volume":"17","author":"F Pacelli","year":"2010","unstructured":"Pacelli F et al (2010) Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy. Ann Surg Oncol 17(1):152\u2013162","journal-title":"Ann Surg Oncol"},{"key":"3614_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/1471-2407-14-337","volume":"14","author":"CK Wong","year":"2014","unstructured":"Wong CK et al (2014) Health-related quality of life and risk of colorectal cancer recurrence and all-cause death among advanced stages of colorectal cancer 1-year after diagnosis. BMC Cancer 14:337","journal-title":"BMC Cancer"},{"issue":"36","key":"3614_CR28","doi-asserted-by":"publisher","first-page":"5770","DOI":"10.1200\/JCO.2007.12.5294","volume":"25","author":"A Bottomley","year":"2007","unstructured":"Bottomley A et al (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25(36):5770\u20135776","journal-title":"J Clin Oncol"},{"key":"3614_CR29","doi-asserted-by":"crossref","unstructured":"Braun, D.P., D. Gupta, and E.D. Staren, Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC cancer, 2011. 11(Journal Article): p. 353.","DOI":"10.1186\/1471-2407-11-353"},{"issue":"5","key":"3614_CR30","doi-asserted-by":"publisher","first-page":"538","DOI":"10.5732\/cjc.009.10455","volume":"29","author":"Y Dai","year":"2010","unstructured":"Dai Y et al (2010) Survival analysis of 220 patients with completely resected stage-II non-small cell lung cancer. Chin J Cancer 29(5):538\u2013544","journal-title":"Chin J Cancer"},{"issue":"10","key":"3614_CR31","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1038\/bjc.2014.208","volume":"110","author":"DE Ediebah","year":"2014","unstructured":"Ediebah DE et al (2014) Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer 110(10):2427\u20132433","journal-title":"Br J Cancer"},{"issue":"11","key":"3614_CR32","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1093\/annonc\/mdl183","volume":"17","author":"F Efficace","year":"2006","unstructured":"Efficace F et al (2006) Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol 17(11):1698\u20131704","journal-title":"Ann Oncol"},{"issue":"5","key":"3614_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2354.2012.01332.x","volume":"21","author":"D Gupta","year":"2012","unstructured":"Gupta D, Braun DP, Staren ED (2012) Association between changes in quality of life scores and survival in non-small cell lung cancer patients. Eur J Cancer Care (Engl) 21(5):614\u2013622","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"2","key":"3614_CR34","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<333::AID-CNCR10>3.0.CO;2-Q","volume":"85","author":"JE Herndon 2nd","year":"1999","unstructured":"Herndon JE 2nd et al (1999) Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? Cancer 85(2):333\u2013340","journal-title":"Cancer"},{"issue":"25","key":"3614_CR35","doi-asserted-by":"publisher","first-page":"4116","DOI":"10.1200\/JCO.2008.16.7460","volume":"26","author":"JE Herndon 2nd","year":"2008","unstructured":"Herndon JE 2nd et al (2008) Patient education level as a predictor of survival in lung cancer clinical trials. J Clin Oncol 26(25):4116\u20134123","journal-title":"J Clin Oncol"},{"key":"3614_CR36","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1186\/1471-2458-12-790","volume":"12","author":"TC Li","year":"2012","unstructured":"Li TC et al (2012) Quality of life predicts survival in patients with non-small cell lung cancer. BMC Public Health 12:790","journal-title":"BMC Public Health"},{"issue":"5","key":"3614_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/00000421-199910000-00006","volume":"22","author":"SJ Martins","year":"1999","unstructured":"Martins SJ, Pereira JR (1999) Clinical factors and prognosis in non-small cell lung cancer. Am J Clin Oncol 22(5):453\u2013457","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"3614_CR38","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/pon.1259","volume":"17","author":"N Nakaya","year":"2008","unstructured":"Nakaya N et al (2008) Negative psychological aspects and survival in lung cancer patients. Psycho-Oncology 17(5):466\u2013473","journal-title":"Psycho-Oncology"},{"issue":"15","key":"3614_CR39","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1200\/JCO.2004.09.147","volume":"22","author":"AK Nowak","year":"2004","unstructured":"Nowak AK, Stockler MR, Byrne MJ (2004) Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core quality of life questionnaire and lung cancer module. J Clin Oncol 22(15):3172\u20133180","journal-title":"J Clin Oncol"},{"issue":"5","key":"3614_CR40","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1093\/ejcts\/ezs532","volume":"43","author":"C Pompili","year":"2013","unstructured":"Pompili C et al (2013) Preoperative quality of life predicts survival following pulmonary resection in stage I non-small-cell lung cancer. European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery 43(5):905\u2013910","journal-title":"European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery"},{"issue":"6 Suppl","key":"3614_CR41","doi-asserted-by":"publisher","first-page":"324S","DOI":"10.1378\/chest.106.6_Supplement.324S","volume":"106","author":"JC Ruckdeschel","year":"1994","unstructured":"Ruckdeschel JC, Piantadosi S (1994) Quality of life in lung cancer surgical adjuvant trials. Chest 106(6 Suppl):324S\u2013328S","journal-title":"Chest"},{"issue":"3","key":"3614_CR42","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1349-7006.2006.00159.x","volume":"97","author":"K Saito-Nakaya","year":"2006","unstructured":"Saito-Nakaya K et al (2006) Marital status, social support and survival after curative resection in non-small-cell lung cancer. Cancer Sci 97(3):206\u2013213","journal-title":"Cancer Sci"},{"issue":"7","key":"3614_CR43","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/BF02629515","volume":"9","author":"RS Schonwetter","year":"1994","unstructured":"Schonwetter RS, Robinson BE, Ramirez G (1994) Prognostic factors for survival in terminal lung cancer patients. J Gen Intern Med 9(7):366\u2013371","journal-title":"J Gen Intern Med"},{"issue":"3","key":"3614_CR44","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/sj.bjc.6600466","volume":"87","author":"HR Scott","year":"2002","unstructured":"Scott HR et al (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3):264\u2013267","journal-title":"Br J Cancer"},{"issue":"1","key":"3614_CR45","first-page":"25","volume":"65","author":"KE Stanley","year":"1980","unstructured":"Stanley KE (1980) Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 65(1):25\u201332","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"3614_CR46","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1556-0864(15)30411-1","volume":"1","author":"S Sundstrom","year":"2006","unstructured":"Sundstrom S et al (2006) Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 1(8):816\u2013824","journal-title":"Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer"},{"issue":"1","key":"3614_CR47","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/cncr.24703","volume":"116","author":"XS Wang","year":"2010","unstructured":"Wang XS et al (2010) Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer 116(1):137\u2013145","journal-title":"Cancer"},{"issue":"10","key":"3614_CR48","first-page":"5173","volume":"45","author":"LJ Emrich","year":"1985","unstructured":"Emrich LJ et al (1985) Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 45(10):5173\u20135179","journal-title":"Cancer Res"},{"issue":"4","key":"3614_CR49","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0022-5347(17)41039-1","volume":"141","author":"HJ de Voogt","year":"1989","unstructured":"de Voogt HJ et al (1989) Multivariate analysis of prognostic factors in patients with advanced prostatic cancer: results from 2 European Organization for Research on treatment of cancer trials. J Urol 141(4):883\u2013888","journal-title":"J Urol"},{"issue":"5","key":"3614_CR50","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/jama.1991.03460050072023","volume":"265","author":"GW Chodak","year":"1991","unstructured":"Chodak GW et al (1991) Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex study group. JAMA : the journal of the American Medical Association 265(5):618\u2013621","journal-title":"JAMA : the journal of the American Medical Association"},{"issue":"2","key":"3614_CR51","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1464-410X.1992.tb15491.x","volume":"69","author":"SD Fossa","year":"1992","unstructured":"Fossa SD et al (1992) Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br J Urol 69(2):175\u2013179","journal-title":"Br J Urol"},{"issue":"12","key":"3614_CR52","doi-asserted-by":"publisher","first-page":"2870","DOI":"10.1002\/1097-0142(19921215)70:12<2870::AID-CNCR2820701225>3.0.CO;2-F","volume":"70","author":"DP Petrylak","year":"1992","unstructured":"Petrylak DP et al (1992) Prognostic factors for survival of patients with bidimensionally measurable metastatic hormone-refractory prostatic cancer treated with single-agent chemotherapy. Cancer 70(12):2870\u20132878","journal-title":"Cancer"},{"issue":"6","key":"3614_CR53","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","volume":"14","author":"IF Tannock","year":"1996","unstructured":"Tannock IF et al (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14(6):1756\u20131764","journal-title":"J Clin Oncol"},{"issue":"3","key":"3614_CR54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jnci\/93.3.219","volume":"93","author":"I Thompson","year":"2001","unstructured":"Thompson I et al (2001) Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 93(3):219\u2013225","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3614_CR55","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0302-2838(02)00272-5","volume":"42","author":"TM De Reijke","year":"2002","unstructured":"De Reijke TM, Derobert E (2002) Prognostic factor analysis in patients with advanced prostate cancer treated by castration plus anandron or placebo: a final update. Eur Urol 42(2):139\u2013146","journal-title":"Eur Urol"},{"issue":"1","key":"3614_CR56","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","volume":"2","author":"CM Tangen","year":"2003","unstructured":"Tangen CM et al (2003) Ten-year survival in patients with metastatic prostate cancer. Clinical prostate cancer 2(1):41\u201345","journal-title":"Clinical prostate cancer"},{"issue":"19","key":"3614_CR57","doi-asserted-by":"publisher","first-page":"3877","DOI":"10.1200\/JCO.2004.07.089","volume":"22","author":"L Collette","year":"2004","unstructured":"Collette L et al (2004) Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European organisation for research and treatment of cancer genitourinary group. J Clin Oncol 22(19):3877\u20133885","journal-title":"J Clin Oncol"},{"issue":"15","key":"3614_CR58","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","volume":"23","author":"S Oudard","year":"2005","unstructured":"Oudard S et al (2005) Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 23(15):3343\u20133351","journal-title":"J Clin Oncol"},{"issue":"21","key":"3614_CR59","doi-asserted-by":"publisher","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","volume":"13","author":"AJ Armstrong","year":"2007","unstructured":"Armstrong AJ et al (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13(21):6396\u20136403","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3614_CR60","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.eururo.2007.03.072","volume":"53","author":"A Bamias","year":"2008","unstructured":"Bamias A et al (2008) Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 53(2):323\u2013331","journal-title":"Eur Urol"},{"issue":"15","key":"3614_CR61","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1200\/JCO.2007.15.0367","volume":"26","author":"S Halabi","year":"2008","unstructured":"Halabi S et al (2008) Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26(15):2544\u20132549","journal-title":"J Clin Oncol"},{"issue":"6","key":"3614_CR62","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00520-011-1213-x","volume":"20","author":"DP Braun","year":"2012","unstructured":"Braun DP, Gupta D, Staren ED (2012) Predicting survival in prostate cancer: the role of quality of life assessment. Support Care Cancer 20(6):1267\u20131274","journal-title":"Support Care Cancer"},{"key":"3614_CR63","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1471-2490-13-32","volume":"13","author":"D Gupta","year":"2013","unstructured":"Gupta D, Braun DP, Staren ED (2013) Prognostic value of changes in quality of life scores in prostate cancer. BMC Urol 13:32","journal-title":"BMC Urol"},{"issue":"1","key":"3614_CR64","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","volume":"68","author":"K Fizazi","year":"2015","unstructured":"Fizazi K et al (2015) Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer. Eur Urol 68(1):42\u201350","journal-title":"Eur Urol"},{"issue":"1","key":"3614_CR65","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/0304-3959(91)90141-J","volume":"44","author":"JC Liebeskind","year":"1991","unstructured":"Liebeskind JC (1991) Pain can kill. Pain 44(1):3\u20134","journal-title":"Pain"},{"issue":"10","key":"3614_CR66","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nrn1914","volume":"7","author":"PW Mantyh","year":"2006","unstructured":"Mantyh PW (2006) Cancer pain and its impact on diagnosis, survival and quality of life. Nat Rev Neurosci 7(10):797\u2013809","journal-title":"Nat Rev Neurosci"},{"issue":"19","key":"3614_CR67","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1200\/JCO.2002.02.118","volume":"20","author":"TJ Smith","year":"2002","unstructured":"Smith TJ et al (2002) Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 20(19):4040\u20134049","journal-title":"J Clin Oncol"},{"issue":"6","key":"3614_CR68","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.jpainsymman.2006.08.003","volume":"32","author":"RK Portenoy","year":"2006","unstructured":"Portenoy RK et al (2006) Opioid use and survival at the end of life: a survey of a hospice population. J Pain Symptom Manag 32(6):532\u2013540","journal-title":"J Pain Symptom Manag"},{"issue":"4","key":"3614_CR69","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1097\/ALN.0b013e31824b96a1","volume":"116","author":"AV Bortsov","year":"2012","unstructured":"Bortsov AV et al (2012) Mu-opioid receptor gene A118G polymorphism predicts survival in patients with breast cancer. Anesthesiology 116(4):896\u2013902","journal-title":"Anesthesiology"},{"issue":"4","key":"3614_CR70","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1097\/ALN.0b013e31824b9512","volume":"116","author":"FE Lennon","year":"2012","unstructured":"Lennon FE, Moss J, Singleton PA (2012) The mu-opioid receptor in cancer progression: is there a direct effect? Anesthesiology 116(4):940\u2013945","journal-title":"Anesthesiology"},{"issue":"16","key":"3614_CR71","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1002\/cncr.29460","volume":"121","author":"PA Singleton","year":"2015","unstructured":"Singleton PA et al (2015) The mu opioid receptor: a new target for cancer therapy? Cancer 121(16):2681\u20132688","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-017-3614-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-017-3614-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T08:38:13Z","timestamp":1719045493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-017-3614-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,11]]},"references-count":71,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1007\/s00520-017-3614-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,11]]},"assertion":[{"value":"8 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declared that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}